VANCOUVER, BC / ACCESS Newswire / September 4, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that it intends to complete a non-brokered private placement offering of up to 31,000,000 units ("Units") at a price of $0.05 per Unit for gross proceeds of up to $1,550,000 ("Private Placement").
Each Unit is comprised of one Common Share and one warrant which will be exercisable into one (1) Common Share of the Company (each a "Warrant"). Each Warrant will have a term of five (5) years and will entitle the holder to purchase one (1) Common Share at a price of $0.15 per Common Share following the closing date. The Common Shares and Warrants comprising the Units will be subject to a four-month and one day hold period in accordance with the policies of the Canadian Securities Exchange ("CSE") and applicable securities legislation.
The Company intends to use net proceeds of the Private Placement for working capital requirements.
The Company will pay a finder's fee to qualified finders who assist in selling the Units, in cash or securities or a combination of both, as permitted by CSE policy and applicable securities laws.
The Private Placement is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including approval from the CSE.
For more information about AIML:
For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.
Contact:
Blake Fallis at
(778) 405-0882
info@aiml.health
About AI/ML Innovations Inc.
https://www.aiml.health/
AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.
AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).
On behalf of the Board of Directors:
Paul Duffy, Executive Chairman
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including with respect to the completion of the Private Placement. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of AIML, including the timing and nature of all deliverables associated with the Private Placement and whether the Private Placement will be completed as currently proposed or at all. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.
SOURCE: AI/ML Innovations, Inc.
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aiml-announces-proposed-private-placement-1068691
